Literature DB >> 21791836

Cartilage and chondrocyte pathology in the mucopolysaccharidoses: The role of glycosaminoglycan-mediated inflammation.

Calogera M Simonaro1.   

Abstract

Entities:  

Year:  2010        PMID: 21791836     DOI: 10.3233/PRM-2010-0120

Source DB:  PubMed          Journal:  J Pediatr Rehabil Med        ISSN: 1874-5393


× No keyword cloud information.
  9 in total

1.  The effect of neonatal gene therapy on skeletal manifestations in mucopolysaccharidosis VII dogs after a decade.

Authors:  Elizabeth M Xing; Van W Knox; Patricia A O'Donnell; Tracey Sikura; Yuli Liu; Susan Wu; Margret L Casal; Mark E Haskins; Katherine P Ponder
Journal:  Mol Genet Metab       Date:  2013-04-06       Impact factor: 4.797

2.  Long-term nonsense suppression therapy moderates MPS I-H disease progression.

Authors:  Gwen Gunn; Yanying Dai; Ming Du; Valery Belakhov; Jeyakumar Kandasamy; Trenton R Schoeb; Timor Baasov; David M Bedwell; Kim M Keeling
Journal:  Mol Genet Metab       Date:  2013-12-17       Impact factor: 4.797

3.  Pathogenesis of lumbar spine disease in mucopolysaccharidosis VII.

Authors:  Lachlan J Smith; Guilherme Baldo; Susan Wu; Yuli Liu; Michael P Whyte; Roberto Giugliani; Dawn M Elliott; Mark E Haskins; Katherine P Ponder
Journal:  Mol Genet Metab       Date:  2012-03-30       Impact factor: 4.797

Review 4.  Pathogenesis and treatment of spine disease in the mucopolysaccharidoses.

Authors:  Sun H Peck; Margret L Casal; Neil R Malhotra; Can Ficicioglu; Lachlan J Smith
Journal:  Mol Genet Metab       Date:  2016-06-04       Impact factor: 4.797

Review 5.  Cardiac disease in patients with mucopolysaccharidosis: presentation, diagnosis and management.

Authors:  Elizabeth A Braunlin; Paul R Harmatz; Maurizio Scarpa; Beatriz Furlanetto; Christoph Kampmann; James P Loehr; Katherine P Ponder; William C Roberts; Howard M Rosenfeld; Roberto Giugliani
Journal:  J Inherit Metab Dis       Date:  2011-07-09       Impact factor: 4.982

6.  Biomarkers for prediction of skeletal disease progression in mucopolysaccharidosis type I.

Authors:  Troy C Lund; Terence M Doherty; Julie B Eisengart; Rebecca L Freese; Kyle D Rudser; Ellen B Fung; Bradley S Miller; Klane K White; Paul J Orchard; Chester B Whitley; Lynda E Polgreen
Journal:  JIMD Rep       Date:  2020-12-08

7.  Imaging findings of mucopolysaccharidoses: a pictorial review.

Authors:  Stefano Palmucci; Giancarlo Attinà; Maria Letizia Lanza; Giuseppe Belfiore; Giuseppina Cappello; Pietro Valerio Foti; Pietro Milone; Domenico Di Bella; Rita Barone; Agata Fiumara; Giovanni Sorge; Giovanni Carlo Ettorre
Journal:  Insights Imaging       Date:  2013-05-05

8.  The factors affecting lipid profile in adult patients with Mucopolysaccharidosis.

Authors:  Karolina M Stepien; Fiona J Stewart; Chris J Hendriksz
Journal:  Mol Genet Metab Rep       Date:  2017-05-18

9.  Pilot study of the safety and effect of adalimumab on pain, physical function, and musculoskeletal disease in mucopolysaccharidosis types I and II.

Authors:  Lynda E Polgreen; Alicia Kunin-Batson; Kyle Rudser; Richard K Vehe; Jeanine J Utz; Chester B Whitley; Patricia Dickson
Journal:  Mol Genet Metab Rep       Date:  2017-01-15
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.